Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Inclusion Criteria: * Histologically confirmed Epstein Barr virus-positive lymphoma, including the following subtypes: * Post-transplantation lymphoma * Burkitt's lymphoma * Hodgkin's lymphoma * T-/NK-cell lymphoma * Unresponsive to, or relapsed after, at least 1 prior chemotherapy regimen * Bidimensionally measurable disease by CT scan * At least 1 lesion ≥ 1.5 cm in the greatest diameter * Age 18 and over * ECOG 0-2 OR * Karnofsky 50-100% * Life expectancy More than 3 months * Hematopoietic * Absolute neutrophil count ≥ 1,000/mm\^3 (no growth factor support within the past 4 weeks) * Hemoglobin ≥ 9.0 g/dL * Platelet count ≥ 50,000/mm\^3 (no platelet transfusions within the past 4 weeks) * Hepatic * Bilirubin ≤ 2.0 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN (5 times ULN in patients with liver involvement) * No active hepatitis B or C * Renal * Creatinine clearance ≥ 60 mL/min * Sodium \> 130 mmol/L * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * At least 4 weeks since prior immunotherapy * At least 4 weeks since prior chemotherapy * At least 4 weeks since prior radiotherapy * More than 4 weeks since prior major surgery unless fully recovered * Recovered from all prior therapy * At least 4 weeks since prior investigational agents Exclusion Criteria: * primary or secondary CNS lymphoma or HIV-related lymphoma * known brain metastases * myocardial infarction within the past 6 months * acute ischemia or new conduction system abnormalities by electrocardiogram * symptomatic congestive heart failure * unstable angina pectoris * cardiac arrhythmia * hospitalized * pregnant or nursing * other uncontrolled illness * ongoing or active systemic infection * psychiatric illness or social situation that would preclude study compliance * history of allergic reaction attributable to compounds of similar chemical or biological composition to study drugs * sensitivity to boron, mannitol, bortezomib, or ganciclovir * concurrent corticosteroids (≥ 10 mg of prednisone or equivalent) * concurrent radiotherapy * other concurrent anticancer therapy * other concurrent investigational agents